AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27236200 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Health Practitioner (EHP) intervention
Number of subjects: 276
Study 27236200 — intervention group
Group type: EXPERIMENTAL
Intervention: Future interventions
Number of subjects: 276
Study 26377368 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=12)
Number of subjects: 24
Study 26377368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 24
Study 23885521 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 120
Study 23885521 — intervention group
Group type: COMPARATOR
Intervention: Traditional cholecystectomy
Number of subjects: 120
Study 22479740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 100 mg once daily for 72 hrs
Number of subjects: 65
Study 22479740 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrocortisone 100 mg i.v. 6 hourly for 72 hrs
Number of subjects: 65
Study 23283393 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice BCG vaccinations (0.1 mL intradermal injection, 3 times every 4 weeks)
Number of subjects: 40
Study 23283393 — intervention group
Group type: COMPARATOR
Intervention: Single BCG vaccination (0.1 mL intradermal injection)
Number of subjects: 40
Study 17190103 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 1
Number of subjects: 0
Study 17190103 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 2
Number of subjects: 0
Study 17190103 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 3
Number of subjects: 0
Study 17190103 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 4
Number of subjects: 0
Study 17190103 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 0
Study 15046683 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 794
Study 15046683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794
Study 10753986 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting (successful stenting)
Number of subjects: 14
Study 10753986 — intervention group
Group type: COMPARATOR
Intervention: Carotid stenting (unsuccessful stenting)
Number of subjects: 14
Study 8575136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) at 3-5 mg/kg/day
Number of subjects: 35
Study 8575136 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Methotrexate (MTX) at 2.5 mg every 12 hours for 3 consecutive doses each week up to 15 mg/week
Number of subjects: 35
Study 8575136 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 35
Study 8575136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 35
Study 8575136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) and Methotrexate (MTX)
Number of subjects: 35
Study 2791446 — intervention group
Group type: EXPERIMENTAL
Intervention: 3200 mg ibuprofen
Number of subjects: 12
Study 2791446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 362791 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoinositol
Number of subjects: 59
Study 31273459 — intervention group
Group type: COMPARATOR
Intervention: Not treated by a specialist (RA)
Number of subjects: 0
Study 31273459 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (all three diagnoses)
Number of subjects: 0
Study 31273459 — intervention group
Group type: COMPARATOR
Intervention: Depressive symptoms (axSpA)
Number of subjects: 0
Study 31273459 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims data validity
Number of subjects: 0
Study 28602530 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-mm magnification marker
Number of subjects: 100
Study 28602530 — intervention group
Group type: COMPARATOR
Intervention: Standard 21% magnification
Number of subjects: 100
Study 26001510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate therapy
Number of subjects: 0
Study 26001510 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-delay therapy
Number of subjects: 0
Study 26001510 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICD programming
Number of subjects: 0
Study 26001510 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm A)
Number of subjects: 0
Study 26001510 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm B)
Number of subjects: 0
Study 26001510 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm C)
Number of subjects: 0
Study 24113668 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 263
Study 24113668 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin (b-INS)
Number of subjects: 263
Study 21586650 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (100 mg)
Number of subjects: 120
Study 21586650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18755849 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-variable Modification of Diet in Renal Disease (6-MDRD)
Number of subjects: 155
Study 18755849 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-variable MDRD (4-MDRD)
Number of subjects: 155
Study 18755849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG)
Number of subjects: 155
Study 18755849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault equations corrected for body surface area (CGC)
Number of subjects: 155
Study 16926172 — intervention group
Group type: EXPERIMENTAL
Intervention: new formulation (vitamins B1, B2, B6, B12, and folic acid)
Number of subjects: 325
Study 16926172 — intervention group
Group type: EXPERIMENTAL
Intervention: old formulation (vitamins B1, B2, B6, and B12)
Number of subjects: 325
Study 16926172 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 325
Study 15049015 — intervention group
Group type: EXPERIMENTAL
Intervention: CCG-1991
Number of subjects: 140
Study 15049015 — intervention group
Group type: COMPARATOR
Intervention: Other CCG leukemia studies
Number of subjects: 140
Study 11390122 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 300 microg daily
Number of subjects: 361
Study 11390122 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17 beta‐estradiol (50 microg/day, 2 patches per week)
Number of subjects: 361
Study 9198496 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 22
Study 9198496 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise
Number of subjects: 22
Study 8313635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% griseofulvin spray applied twice daily for 14 days
Number of subjects: 116
Study 8313635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) applied twice daily for 14 days
Number of subjects: 116
Study 8313635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% griseofulvin spray applied once daily for 4 weeks
Number of subjects: 116
Study 8313635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) applied once daily for 4 weeks
Number of subjects: 116
Study 2827545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine
Number of subjects: 25
Study 2827545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with epinephrine
Number of subjects: 25
Study 2827545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% mepivacaine
Number of subjects: 25
Study 31563383 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) combined with integrated neuromuscular inhibition technique (INIT)
Number of subjects: 40
Study 31563383 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise (TE)
Number of subjects: 40
Study 28810251 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg q.d. for 1 month followed by 5 mg q.d. for maintenance
Number of subjects: 100
Study 28810251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg b.i.d. for 1 month followed by 45 mg b.i.d. for maintenance
Number of subjects: 100
Study 28810251 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg q.d. for 1 month followed by standard dose without reduction
Number of subjects: 100
Study 28810251 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Prasugrel, Ticagrelor, Clopidogrel)
Number of subjects: 100
Study 25412795 — intervention group
Group type: EXPERIMENTAL
Intervention: ALV 600 mg QD + PR
Number of subjects: 459
Study 25412795 — intervention group
Group type: EXPERIMENTAL
Intervention: ALV 800 mg QD + PR
Number of subjects: 459
Study 25412795 — intervention group
Group type: EXPERIMENTAL
Intervention: ALV 400 mg BID + PR
Number of subjects: 459
Study 25412795 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PR
Number of subjects: 459
Study 25412795 — intervention group
Group type: COMPARATOR
Intervention: PR alone
Number of subjects: 459
Study 22324720 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% tacrolimus ointment
Number of subjects: 26
Study 22324720 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 26
Study 21691613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold OD
Number of subjects: 41
Study 21691613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti OD
Number of subjects: 41
Study 21691613 — intervention group
Group type: EXPERIMENTAL
Intervention: IFP
Number of subjects: 41
Study 19060425 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg/day)
Number of subjects: 100
Study 19060425 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 100
Study 16795983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor vaccine
Number of subjects: 67
Study 16795983 — intervention group
Group type: COMPARATOR
Intervention: Control group (adjuvant treatment only)
Number of subjects: 67
Study 16795983 — intervention group
Group type: EXPERIMENTAL
Intervention: DTH response positive patients (from tumor vaccine group)
Number of subjects: 67
Study 14515287 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative portal vein infusion (PVI) of 5‐fluorouracil (5‐FU) (1 g 5‐FU plus 5000 units heparin in 1 litre 5 per cent dextrose infused over each 24‐h period for 7 days)
Number of subjects: 3583
Study 14515287 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (timing not specified)
Number of subjects: 3583
Study 14515287 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic cancer
Number of subjects: 3583
Study 14515287 — intervention group
Group type: COMPARATOR
Intervention: Rectal cancer
Number of subjects: 3583
Study 11113418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical force of injection at 90 minutes
Number of subjects: 0
Study 11113418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (hand injection)
Number of subjects: 0
Study 11113418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand injections
Number of subjects: 0
Study 8736564 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lesions
Number of subjects: 0
Study 8736564 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lesions
Number of subjects: 0
Study 8736564 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 1561683 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Number of subjects: 792
Study 1561683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 6229319 — intervention group
Group type: EXPERIMENTAL
Intervention: gallamine (0.29 mg X kg‐1)
Number of subjects: 58
Study 6229319 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (0.04 mg X kg‐1)
Number of subjects: 58
Study 6229319 — intervention group
Group type: EXPERIMENTAL
Intervention: metocurine (0.014 mg X kg‐1)
Number of subjects: 58
Study 6229319 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium (0.007 mg X kg‐1)
Number of subjects: 58
Study 6229319 — intervention group
Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 58
Study 31541422 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 136
Study 31541422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 29145548 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Discharge Team
Number of subjects: 183
Study 29145548 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 183
Study 26915605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefiracetam 900 mg/day for 12 weeks
Number of subjects: 13
Study 26915605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24197880 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test
Number of subjects: 379
Study 24197880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziehl‐Neelsen smear
Number of subjects: 379
Study 24197880 — intervention group
Group type: EXPERIMENTAL
Intervention: MGIT culture
Number of subjects: 379
Study 24197880 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test with vortexing step
Number of subjects: 379
Study 20946966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) + Fludarabine (Flu) 10:30 mg/m²
Number of subjects: 51
Study 20946966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) 40 mg/m²
Number of subjects: 51
Study 20946966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) 20:20 mg/m²
Number of subjects: 51
Study 20946966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) 30:10 mg/m²
Number of subjects: 51
Study 20946966 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent Clo 40 mg/m²
Number of subjects: 51
Study 20946966 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 51
Study 19273465 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with usual care support
Number of subjects: 0
Study 19273465 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with weekly support
Number of subjects: 0
Study 19273465 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 16731880 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based psychosocial intervention (10-session manual-guided support group + 12 additional online sessions)
Number of subjects: 66
Study 16731880 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 66
Study 14760368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed family history data risk assessment model
Number of subjects: 0
Study 14760368 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic nurse specialist assessment model
Number of subjects: 0
Study 14760368 — intervention group
Group type: COMPARATOR
Intervention: Both models of service
Number of subjects: 0
Study 14760368 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cancer worry
Number of subjects: 0
Study 14760368 — intervention group
Group type: COMPARATOR
Intervention: Novel community service
Number of subjects: 0
Study 11399339 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 199
Study 9292621 — intervention group
Group type: EXPERIMENTAL
Intervention: Linopirdine (LPD) 40 mg TID for 4 weeks
Number of subjects: 24
Study 9292621 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID for 4 weeks
Number of subjects: 24
Study 8328789 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin (1 g, orally, twice daily for 14 days)
Number of subjects: 367
Study 8328789 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg, orally, twice daily for 14 days)
Number of subjects: 367
Study 2894730 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fatty acids (linoleic acid and gamma-linolenic acid)
Number of subjects: 34
Study 2894730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 185885 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (6 X 10(‐6) mol/1)
Number of subjects: 8
Study 185885 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropylnoradrenaline (6 X 10(‐6) mol/1)
Number of subjects: 8
Study 185885 — intervention group
Group type: COMPARATOR
Intervention: Basal medium (no lipolytic agents)
Number of subjects: 8
Study 185885 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (13 mmol/1)
Number of subjects: 8
Study 185885 — intervention group
Group type: EXPERIMENTAL
Intervention: Meritene (after re-feeding for one day)
Number of subjects: 8
Study 185885 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropylnoradrenaline (after re-feeding)
Number of subjects: 8
Study 30132785 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 units subcutaneously weekly up to three doses or until ICU discharge
Number of subjects: 606
Study 30132785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 606
Study 28214248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit intervention (changes to convenience, visibility, and attractiveness of fruit in lunchrooms for 6 weeks)
Number of subjects: 10
Study 28214248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no changes made, offered Smarter Lunchrooms training post-intervention)
Number of subjects: 10
Study 26078323 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole‐cell oral cholera vaccine (OCV)
Number of subjects: 216
Study 26078323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 23919622 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus FutureLife porridge nutritional supplement (NS) (388 kcal/day)
Number of subjects: 36
Study 23919622 — intervention group
Group type: COMPARATOR
Intervention: ART alone (Controls)
Number of subjects: 36
Study 22033544 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 60
Study 22033544 — intervention group
Group type: COMPARATOR
Intervention: Non-drained group
Number of subjects: 60
Study 19401546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Epirubicin, and 5-Fluorouracil (CEF)
Number of subjects: 710
Study 19401546 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF)
Number of subjects: 710
Study 17942469 — intervention group
Group type: EXPERIMENTAL
Intervention: Including Intent to Attend as a covariate in mixed-effects outcome analyses
Number of subjects: 0
Study 17942469 — intervention group
Group type: COMPARATOR
Intervention: Not including Intent to Attend as a covariate in mixed-effects outcome analyses
Number of subjects: 0
Study 15058405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene care regimen
Number of subjects: 30
Study 15058405 — intervention group
Group type: COMPARATOR
Intervention: Pre-test OAG scores
Number of subjects: 30
Study 15058405 — intervention group
Group type: COMPARATOR
Intervention: Post-test OAG scores
Number of subjects: 30
Study 11273790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after oxygen (FiO(2)1.0)
Number of subjects: 12
Study 11273790 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 12
Study 11273790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after hypoxic gas mixture (FiO(2)0.15)
Number of subjects: 12
Study 9394634 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition introduced early in training
Number of subjects: 0
Study 9394634 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition introduced late in training
Number of subjects: 0
Study 9394634 — intervention group
Group type: COMPARATOR
Intervention: No competition
Number of subjects: 0
Study 9394634 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size and timing of competition instructions
Number of subjects: 0
Study 7525634 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified prostate-specific antigen (PSA)
Number of subjects: 0
Study 7525634 — intervention group
Group type: COMPARATOR
Intervention: Seminal plasma (SP)
Number of subjects: 0
Study 7525634 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified PSA
Number of subjects: 0
Study 3496202 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy of esophageal varices
Number of subjects: 49
Study 3496202 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 49
Study 29329058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268
Study 29329058 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 268
Study 29329058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBASP and SP
Number of subjects: 268
Study 26933398 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB + Whey protein (3 g/day HMB and 36.6 g/day whey protein)
Number of subjects: 18
Study 26933398 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 18
Study 26933398 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (36.6 g/day)
Number of subjects: 18
Study 25633712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of 0.2% resiquimod gel (arm B)
Number of subjects: 20
Study 25633712 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (arm A)
Number of subjects: 20
Study 25633712 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 protein plus Montanide
Number of subjects: 20
Study 25633712 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 protein plus Montanide with or without topical resiquimod
Number of subjects: 20
Study 23074313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Number of subjects: 60
Study 23074313 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus dosing of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Number of subjects: 60
Study 23074313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics
Number of subjects: 60